Publications by authors named "Shaomei Feng"
Article Synopsis
- Richter transformation poses a continued risk for chronic lymphocytic leukemia (CLL) patients, even with advancements in targeted therapies like Bruton's tyrosine kinase inhibitor, particularly in a reported case of a 61-year-old male who experienced this change post-treatment.
- After stopping ibrutinib during the COVID-19 pandemic, the patient developed a related plasmablastic lymphoma (PBL), diagnosed through histological analysis of a tumor in the supraclavicular area and bone marrow infiltration.
- The patient underwent treatment with a combination of CHP, venetoclax, and brentuximab vedotin, followed by successful BCMA CAR-T cell therapy, resulting in complete remission and highlighting the potential
Background And Aims: Patients with relapsed/refractory aggressive B-cell lymphoma(r/r aBCL)who progressed after CD19-specific chimeric antigen receptor T-cell therapy (CD19CART) had a poor prognosis. Application of CAR T-cells targeting a second different antigen (CD20) expressed on the surface of B-cell lymphoma as subsequent anti-cancer salvage therapy (CD20-SD-CART) is also an option. This study aimed to evaluate the survival outcome of CD20-SD-CART as a salvage therapy for CD19 CART treatment failure.
View Article and Find Full Text PDFThe prognosis of patients diagnosed with relapsed or refractory (R/R) T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) has consistently been unsatisfactory, with limited treatment options. As reports, the CAG regimen can serve as a salvage treatment for R/R T-ALL/LBL, but there remains a subset of patients who do not benefit from it. Recent studies have indicated that daratumumab (Dara) and venetoclax (Ven) may offer promising therapeutic benefits for T-ALL/LBL.
View Article and Find Full Text PDFArticle Synopsis
- * Phage-based nanoplatforms are gaining attention for their structured design, high efficiency, and ability to deliver therapeutic peptides, enhancing drug delivery specifically to tumors.
- * This review explores phage structure and biology, highlighting their potential as effective alternatives to traditional drug delivery methods, particularly in overcoming barriers to treatment.
Objective: Meta-analysis was performed to evaluate the prognostic factors in tumor patients treated with immune checkpoint inhibitors (ICIs) under antibiotic exposure.
Method: Literature on the effect of antibiotics on the prognosis of tumor patients receiving ICIs was retrieved from Pubmed, Cochrane Library, EMbase, EBSCO Evidence-Based Medicine Database, China Biomedical Literature Database (CBM), and China National Knowledge Network (CNKI), and relevant influencing factors were extracted. Meta-analysis of efficacy was performed using RevMan 5.
Objective: The objective is to explore the effectiveness and safety of CAR T-cell therapy in advanced relapsed/refractory central nervous system B-cell lymphoma and compare the impact of autologous stem cell transplantation (ASCT) plus CAR T-cell therapy versus sequential CART therapy on the survival of patients.
Methods: The retrospective analysis was based on the data of 17 patients with advanced relapsed/refractory central nervous system B-cell lymphoma. Bridging chemotherapy was applied before CAR T-cell infusion to further reduce the tumor burden.
Objectives: Flow cytometry (FC) is a critical diagnostic approach for guiding targeted chemotherapy and cellular immunotherapy for relapsed and refractory lymphoma patients. The aim of the study was to investigate the value of ultrasound-guided fine needle aspiration (FNA) to improve the quality of FC specimens in relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL).
Methods: Twenty patients with R/R DLBCL after standard treatment were included.
Objective: To observe the clinical efficacy and side effects of brentuximab vedotin (BV) plus chlormethine hydrochloride (CH) in patients with relapsed and refractory Hodgkin lymphoma (HL) after failure with BV alone.
Methods: From March, 2014 to December, 2014, 6 patients who failed with BV monotherapy were enrolled in this study. The chemotherapy regimen consisted of BV (1.